Professor A. Mark Richards, Our people, University of Otago, Christchurch, University of Otago, New Zealand

Professor

BA (Massey) MB ChB (Otago) MD(Otago,) PhD(Otago) DSc (Otago) FRACP FRCP FRSNZ

Department of Medicine
University of Otago, Christchurch
PO Box 4345
Christchurch
New Zealand

Mark Richards is the director of the Christchurch Heart Institute.

He coordinates and directs multi-disciplinary programmes of grant-funded translational cardiovascular research which seek to improve diagnostic, prognostic and therapeutic options in heart disease.

He is pursuing studies of epidemiological, molecular biological, neurohormonal and therapeutic aspects of acute and chronic cardiovascular disorders including hypertension, coronary syndromes, and the full spectrum of heart failure.

Richards holds the Heart Foundation of New Zealand’s Chair in Cardiovascular Studies.

He also holds joint appointments at the University of Otago and the National University of Singapore’s Cardiovascular Research Institute.
Email mdcarthu@nus.edu.sg (University of Singapore)

Current roles

Director, The Christchurch Heart Institute
Consultant Cardiologist, The Canterbury District Health Board

Research interests

Neurohormonal physiology and pathophysiology in cardiovascular health and disease
Heart Failure
Acute Coronary Syndromes
Hypertension
Vasoactive Hormones
The Cardiac Natriuretic Peptides

^ Top of page

Publications

Charles, C. J., Lee, P., Li, R. R., Yeung, T., Ibraham Mazlan, S. M., Tay, Z. W., … Richards, A. M. (2020). A porcine model of heart failure with preserved ejection fraction: Magnetic resonance imaging and metabolic energetics. ESC Heart Failure, 7, 93-103. doi: 10.1002/ehf2.12536

Mahmoodi, B. K., Tragante, V., Kleber, M. E., Holmes, M. V., Schmidt, A. F., McCubrey, R. O., … Pilbrow, A. P., … Richards, A. M., … Cameron, V. A., … Patel, R. (2020). Association of factor V Leiden with subsequent atherothrombotic events: A GENIUS-CHD study of individual participant data. Circulation, 142, 546-555. doi: 10.1161/circulationaha.119.045526

Aimo, A., Januzzi, Jr, J. L., Vergaro, G., Richards, A. M., Lam, C. S. P., Latini, R., … Troughton, R., … Edmin, M. (2020). Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. European Journal of Heart Failure. Advance online publication. doi: 10.1002/ejhf.1701

Templeton, E. M., Cameron, V. A., Pickering, J. W., Richards, A. M., & Pilbrow, A. P. (2020). Emerging microRNA biomarkers for acute kidney injury in acute decompensated heart failure. Heart Failure Reviews. Advance online publication. doi: 10.1007/s10741-020-09928-w

Huang, W., Teng, T.-H. K., Tay, W. T., Richards, A. M., Kadam, U., Lawson, C. A., … Lam, C. S. P. (2020). Patient-reported outcomes in heart failure with preserved vs. reduced ejection fraction: Focus on physical independence. ESC Heart Failure. Advance online publication. doi: 10.1002/ehf2.12950

Chapter in Book - Research
Chapter in Book - Other
Journal - Research Article

Chapter in Book - Research

Pemberton, C. J., Charles, C. J., & Richards, A. M. (2017). Cardiac natriuretic peptides. In J. C. Schisler, C. H. Lang & M. S. Willis (Eds.), Endocrinology of the heart in health and disease. (pp. 3-39). Elsevier. doi: 10.1016/B978-0-12-803111-7.00001-4

Richards, M., & Rademaker, M. (2013). Urocortins. In A. Kastin (Ed.), Handbook of biologically active peptides. (2nd ed.) (pp. 1428-1436). San Diego, CA: Academic Press. doi: 10.1016/B978-0-12-385095-9.00194-9

Richards, A. M., Troughton, R. W., & Nicholls, M. G. (2011). Natriuretic peptides for guidance of acute and chronic heart failure therapy. In J. L. Januzzi (Ed.), Cardiac biomarkers in clinical practice. (pp. 559-580). Sudbury, MA: Jones & Bartlett.

Richards, A. M. (2009). What we may expect from biomarkers in heart failure. In E. Braunwald (Ed.), Biomarkers in heart failure: An issue of heart failure clinics (Vol.5-4). (pp. 463-470). Philadelphia, PA: Saunders. doi: 10.1016/j.hfc.2009.04.011

Troughton, R. W., & Richards, A. M. (2008). Natriuretic peptides for disease monitoring in patients with chronic heart failure. In J. A. de Lemos (Ed.), Biomarkers in heart disease. (pp. 140-160). Malden, MA: Blackwell.

Nicholls, M. G., & Richards, A. M. (2008). High-risk subgroups: Diabetes and hypertension. In A. Bayés-Genís & J. L. Januzzi (Eds.), NT-proBNP as a biomarker in cardiovascular diseses. (pp. 173-182). Thomson Reuters.

Troughton, R. W., & Richards, A. M. (2008). Outpatient monitoring and treatment of chronic heart failure guided by NT-proBNP measurement. In A. Bayés-Genís & J. L. Januzzi (Eds.), NT-proBNP as a biomarker in cardiovascular diseases. (pp. 91-100). Thomson Reuters.

Nicholls, M. G., & Richards, A. M. (2004). Looking at the adrenals as a primary source. In Handbook of Hypertension: Vol. 22. Hypertension in the Twentieth Century: Concepts and Achievements. (pp. 104-122). Amsterdam: Elsevier.

Lainchbury, J. G., & Richards, A. M. (2003). Exercise testing in the assessment of chronic congestive heart failure. In P. Mills (Ed.), Education in heart, volume 3. (pp. 56-64). London: BMJ Books.

Richards, M., & Nicholls, G. (2003). Endocrine causes of hypertension. In R. J. Johnson & J. Feehally (Eds.), Comprehensive clinical nephrology. (2nd ed.) (pp. 529-541). London, UK: Mosby.

Nicholls, M. G., Richards, A. M., & Yandle, T. G. (2002). The renin-angiotensin system. In G. Mancia, J. Chalmers, S. Julius, T. Saruta, M. Weber, A. Ferrari & I. Wilkinson (Eds.), Manual of Hypertension. (pp. 77-95). London: Churchill Livingstone.

Richards, A. M., Lainchbury, J. G., Nicholls, M. G., & Rademaker, M. T. (2000). Adrenomedullin in heart failure: Biochemical curiosity or pathophysiological player? In J. J. V. McMurray & J. G. F. Cleland (Eds.), Heart Failure in Clinical Practice. (2nd ed.) (pp. 105-125). London: Martin Dunitz.

Richards, A. M. (1999). Combined angiotensin convertin enzyme inhibition and angiotensin II type 1 receptor antagonism. In M. G. Nicholls, H. R. Brunner, H. Ikram, C. S. Sweet & J. F. Walker (Eds.), 100 Years of the Renin-Angiotensin System. (pp. 90-95). New Jersey, USA: Merck & Co..

Richards, A. M., Nicholls, M. G., & Troughton, R. W. (1999). The pharmacotherapy of diuretics. In N. Sharpe (Ed.), Heart Failure Management 2000. (pp. 43-60). London: Martin Dunitz.

Nicholls, M. G., Richards, A. M., & Begg, E. J. (1999). Hypertension as a cause of heart failure: Is it still important? In J. J. V. McMurray & J. G. F. Cleland (Eds.), Heart Failure in Clinical Practice. (pp. 19-32). London: Martin Dunitz.

Nicholls, M. G., Richards, A. M., & Begg, E. J. (1998). Hypertension as a cause of heart failure - is it still important? In J. J. V. McMurray & J. G. F. Cleland (Eds.), Heart Failure in Clinical Practice (Second Edition). London: Dunitz.

Espiner, E. A., Richards, A. M., & Nicholls, M. G. (1998). Physiology of natriuretic peptides. In E. R. Levin & J. Nadler (Eds.), Endocrinology of Cardiovascular Function. Kluwer Academic Publishers.

Nicholls, M. G., Richards, A. M., & Begg, E. J. (1997). Hypertension and heart failure. In A. Zanchetti & et al (Eds.), Hypertension and the heart. (pp. 273-279). New York: Plenum Press.

Lainchbury, J. G., Richards, A. M., & Nicholls, M. G. (1997). Brain natriuretic peptide in heart failure. In Atrial Natriuretic Peptides. (pp. 151-158).

Nicholls, M. G., Pidgeon, G. B., Lewis, L. K., & Richards, A. M. (1996). Ouabain, adrenal glands and hypertension. In G. P. Vinson & D. C. Anderson (Eds.), Adrenal Glands, Vascular System and Hypertension. (pp. 115-121). Bradley Stoke, Bristol, U.K.: Journal of Endocrinology Limited.

^ Top of page

Chapter in Book - Other

Richards, M., Troughton, R., Espiner, E., Cameron, V., Ellmers, L., Pilbrow, A., Charles, C., Rademaker, M., Pemberton, C., & Yandle, T. (2013). Christchurch Heart Institute. In P. Joyce, G. Nicholls, K. Thomas & T. Wilkinson (Eds.), The Christchurch experience: 40 years of research and teaching. (pp. 68-74). Christchurch, New Zealand: University of Otago.

Nicholls, M. G., & Richards, A. M. (2007). Endocrine causes of hypertension. In J. Feehally, J. Floege & R. J. Johnson (Eds.), Comprehensive clinical nephrology. (3rd ed.) (pp. 443-452). Philadelphia: Mosby.

Richards, A. M., Nicholls, M. G., & Troughton, R. W. (2000). Diuretic therapy: Essential in heart failure. In N. Sharpe (Ed.), Heart failure management. (pp. 43-59). United Kingdom: Martin Dunitz.

Nicholls, M. G., Richards, A. M., & Begg, E. J. (2000). Hypertension as a cause of heart failure: Is it still important? In J. J. V. McMurray & J. G. F. Cleland (Eds.), Heart failure in clinical practice. (2nd ed.) (pp. 19-31). United Kingdom: Martin Dunitz.

^ Top of page

Journal - Research Article

Appleby, S., Chew-Harris, J., Troughton, R. W., Richards, A. M., & Pemberton, C. J. (2020). Analytical and biological assessment of circulating human erythroferrone. Clinical Biochemistry, 79, 41-47. doi: 10.1016/j.clinbiochem.2020.02.001

Chan, M. Y., Efthymios, M., Tan, S. H., Pickering, J. W., Troughton, R., Pemberton, C., … Pilbrow, A., & Richards, A. M. (2020). Prioritizing candidates of post-myocardial infarction heart failure using plasma proteomics and single-cell transcriptomics. Circulation. Advance online publication. doi: 10.1161/circulationaha.119.045158

Ellmers, L. J., Templeton, E. M., Pilbrow, A. P., Frampton, C., Ishii, I., Moore, P. K., … Richards, A. M., & Cameron, V. A. (2020). Hydrogen sulfide treatment improves post-infarct remodeling and long-term cardiac function in CSE knockout and wild-type mice. International Journal of Molecular Sciences, 21(12), 4284. doi: 10.3390/ijms21124284

Verbree-Willemsen, L., Zhang, Y.-N., Ibrahim, I., Ooi, S. B. S., Wang, J.-W., Mazlan, M. I., … Richards, A. M., … de Kleijn, D. P. V. (2020). Extracellular vesicle Cystatin C and CD14 are associated with both renal dysfunction and heart failure. ESC Heart Failure. Advance online publication. doi: 10.1002/ehf2.12699

Pickering, J. W., Young, J. M., George, P. M., Pemberton, C. J., Watson, A., Aldous, S. J., … Troughton, R. W., Richards, A. M., … Than, M. P. (2020). Early kinetic profiles of troponin I and T measured by high-sensitivity assays in patients with myocardial infarction. Clinica Chimica Acta, 505, 15-25. doi: 10.1016/j.cca.2020.02.009

Woo, C. C., Liu, W., Lin, X. Y., Dorajoo, R., Lee, K. W., Richards, A. M., … Sorokin, V. (2020). The interaction between 30b-5p miRNA and MBNL1 mRNA is involved in vascular smooth muscle cell differentiation in patients with coronary atherosclerosis. International Journal of Molecular Sciences, 21, 11. doi: 10.3390/ijms21010011

MacDonald, M. R., Tay, W. T., Teng, T.-H. K., Anand, I., Ling, L. H., Yap, J., … ASIAN-HF investigators, Richards, A. M., & Lam, C. S. P. (2020). Regional variation of mortality in heart failure with reduced and preserved ejection fraction across Asia: Outcomes in the ASIAN-HF registry. Journal of the American Heart Association, 9(1), e012199. doi: 10.1161/jaha.119.012199

Kuan, W. S., Ibrahim, I., Chan, S. P., Li, Z., Liew, O. W., Frampton, C., Troughton, R., Pemberton, C. J., … Richards, A. M. (2020). Mid-regional pro-adrenomedullin outperforms N-terminal pro-B-type natriuretic peptide for the diagnosis of acute heart failure in the presence of atrial fibrillation. European Journal of Heart Failure, 22, 692-700. doi: 10.1002/ejhf.1660

Mbikou, P., Rademaker, M. T., Charles, C. J., Richards, M. A., & Pemberton, C. J. (2020). Cardiovascular effects of DWORF (dwarf open reading frame) peptide in normal and ischaemia/reperfused isolated rat hearts. Peptides, 124, 170192. doi: 10.1016/j.peptides.2019.170192

Tan, E. S. J., Goh, V., Santema, B. T., Tay, W. T., Teng, T.-H. K., Yap, J., … Richards, A. M., & Lam, C. S. P. (2020). Ethnic differences in atrial fibrillation among patients with heart failure in Asia. ESC Heart Failure, 7, 1419-1429. doi: 10.1002/ehf2.12696

Yip, C., Seneviratna, A., Tan, S.-H., Khaing, T., Chan, S.-P., Loh, J., … Richards, A. M., & Chan, M. Y. (2020). Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation. Journal of Thrombosis & Thrombolysis, 50, 421-429. doi: 10.1007/s11239-020-02066-y

Ouwerkerk, W., Teng, T.-H. K., Tromp, J., Tay, W. T., Cleland, J. G., van Veldhuisen, D. J., … Richards, A. M., … Lam, C. S. P. (2020). Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: Insights from BIOSTAT-CHF and ASIAN-HF registries. European Journal of Heart Failure. Advance online publication. doi: 10.1002/ejhf.1869

Rademaker, M. T., Scott, N. J. A., Koh, C. Y., Manjunatha Kini, R., & Richards, A. M. (2020). Natriuretic peptide analogues with distinct vasodilatory or renal activity: Integrated effects in health and experimental heart failure. Cardiovascular Research. Advance online publication. doi: 10.1093/cvr/cvaa052

Wong, L. L., Saw, E. L., Lim, J. Y., Zhou, Y., Richards, A. M., & Wang, P. (2019). MicroRNA Let-7d-3p contributes to cardiac protection via targeting HMGA2. International Journal of Molecular Sciences, 20(7), 1522. doi: 10.3390/ijms20071522

Charles, C. J., Jardine, D. L., Rademaker, M. T., & Richards, A. M. (2019). Adrenomedullin 2 increases cardiac sympathetic nerve activity in parallel to heart rate in normal conscious sheep. Physiological Reports, 7(10), e14096. doi: 10.14814/phy2.14096

Scott, N. J. A., Rademaker, M. T., Charles, C. J., Espiner, E. A., & Richards, A. M. (2019). Hemodynamic, hormonal, and renal actions of phosphodiesterase-9 inhibition in experimental heart failure. JACC, 74(7), 889-901. doi: 10.1016/j.jacc.2019.05.067

Tan, E. S. J., Tay, W. T., Teng, T.-H. K., Sim, D., Leong, K. T. G., Yeo, P. S. D., … Troughton, R. W., … Richards, A. M., … Lam, C. S. P. (2019). Ethnic differences in atrial fibrillation in patients with heart failure from Asia-Pacific. Heart, 105, 842-847. doi: 10.1136/heartjnl-2018-314077

Wong, L. L., Zou, R., Zhou, L., Lim, J. Y., Phua, D. C. Y., Liu, C., … Troughton, R., Cameron, V. A., … Richards, A. M. (2019). Combining circulating microRNA and NT-proBNP to detect and categorize heart failure subtypes. JACC, 73(11), 1300-1313. doi: 10.1016/j.jacc.2018.11.060

Patel, R. S., Schmidt, A. F., Tragante, V., McCubrey, R. O., Holmes, M. V., Howe, L. J., … Pilbrow, A. P., … Richards, A. M., … Cameron, V. A., … Asselbergs, F. W. (2019). Association of chromosome 9p21 with subsequent coronary heart disease events: A GENIUS-CHD study of individual participant data. Circulation: Genomic & Precision Medicine, 12(4), 161-172. doi: 10.1161/circgen.119.002471

Yap, J., Tay, W. T., Teng, T.-H. K., Anand, I., Richards, A. M., Ling, L. H., … Lam, C. S. P. (2019). Association of diabetes mellitus on cardiac remodeling, quality of life, and clinical outcomes in heart failure with reduced and preserved ejection fraction. Journal of the American Heart Association, 8(17), e013114. doi: 10.1161/JAHA.119.013114

Lewis, L. K., Raudsepp, S. D., Prickett, T. C. R., Yandle, T. G., Doughty, R. N., Frampton, C. M., Pemberton, C. J., & Richards, A. M. (2019). ProBNP that is not glycosylated at threonine 71 is decreased with obesity in patients with heart failure. Clinical Chemistry, 65(9), 1115-1124. doi: 10.1373/clinchem.2019.302547

More publications...